catabasis
CONNECTION

Issue 24 | February 2020

Exploring Edasalonexent Effects on the Heart

February is all about the heart and that's a big focus for us, too! Because cardiac function is so vital to those affected by Duchenne, we're passionate to learn more about the heart and edasalonexent in our Phase 3 PolarisDMD trial.

In young boys affected by Duchenne, tachycardia (which is an elevated resting heart rate) is an early manifestation of cardiac disease. In our Phase 2 MoveDMD trial and open-label extension, we saw initial results suggesting that heart rate significantly decreased from baseline in boys receiving edasalonexent to approximately the average rate for unaffected boys.

COMING TOGETHER TO OBSERVE RARE DISEASE DAY

Each year on the last day of February, we support Rare Disease Day to raise awareness for those affected by rare diseases across the globe. The Catabasis team is proud of this tradition and to be a part of the Duchenne community each and every day.

For more information on Rare Disease Day, and to find an event near you, visit rarediseaseday.org

ABOUT EDASALONEXENT

In Duchenne, the loss of dystrophin leads to chronic activation of NF-kB, which is a key driver of skeletal and cardiac muscle disease progression. By inhibiting NF-kB, edasalonexent has the potential to decrease inflammation and fibrosis, promote muscle regeneration, and slow disease progression. Edasalonexent is being developed as both a monotherapy and for use along with other therapies, including exon-skipping therapies and other dystrophin-targeted therapies in development such as gene therapy.

The Phase 3 PolarisDMD trial and GalaxyDMD open-label extension study are both ongoing.

Results for PolarisDMD are expected in the fourth quarter of 2020.

POLARIS DMD GALAXY DMD

MAKING COMMUNITY CONNECTIONS

CureDuchenne Cares Workshops on **March 14th in Phoenix, AZ**. Learn all about these immersive, educational workshops at **www.cureduchenne.org/workshops**

Jett Foundation Family Workshop in **Philadelphia, PA on March 7th**. Learn all about Jett Foundation's national education program at **www.jettfoundation.org/familyworkshops**

Muscular Dystrophy Association Clinical and Scientific Conference from **March 21st through 25th in Orlando, FL**. This annual event convenes everyone at the leading edge of research and care—academics, researchers, clinicians, allied health professionals, advocates, and industry leaders—to meet, collaborate, and share learnings. For more information, go to **www.mda.org/conferences/2020-clinical-and-scientific-conference**

The PPMD End Duchenne Tour in **Atlanta, GA on March 14th**. To learn all about PPMD's efforts to reach every single family facing a Duchenne diagnosis in the US, visit **www.parentprojectmd.org/get-involved/attend-events/end-duchenne-tour**

Stay in touch!

Join our mailing list: http://www.catabasis.com/patients-families/for-further-information.php

For trial-related questions: DMDtrials@catabasis.com

Follow us on social media: @CatabasisPharma.

The information provided here is for parents and caregivers of boys with Duchenne muscular dystrophy. Edasalonexent is an investigational drug that is not yet approved in any territory.

catabasis GALAXY DMD POLARIS DMD